[ad_1]
San Francisco, December 7, 2021 (Global News Agency)-Hagens Berman urges Reata Pharmaceuticals, Inc. (Nasdaq:straight) Investors who have suffered heavy losses Submit your loss immediately.
| access: www.hbsslaw.com/investor-fraud/RETA | |
| Contact a lawyer immediately: RETA@hbsslaw.com | |
| 844-916-0895 | |
Reata Pharmaceuticals, Inc. (RETA) survey:
The focus of the investigation is the statement by Reata and senior management regarding the company’s Phase 3 (CARDINAL) study and related new drug application (“NDA”) of the company’s evaluation of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome.
In the past, the company and its management claimed that the CARDINAL study showed that bardoxolone reached its primary and secondary endpoints, increasing the potential of this therapeutic agent as the first to obtain regulatory approval…
The full story can be found on Benzinga.com
[ad_2]
Source link
